

Nobuhiro Tsuchiya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7974928/publications.pdf>

Version: 2024-02-01

23
papers

841
citations

840776

11
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

1466
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarkers for the early diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 10573.	3.3	377
2	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. <i>Oncolimmunology</i> , 2016, 5, e1129483.	4.6	125
3	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. <i>Oncolimmunology</i> , 2017, 6, e1346764.	4.6	69
4	Cancer immunotherapy targeted glypican-3 or neoantigens. <i>Cancer Science</i> , 2018, 109, 531-541.	3.9	40
5	Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. <i>Oncolimmunology</i> , 2018, 7, e1377872.	4.6	39
6	Potentiality of immunotherapy against hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 10314.	3.3	32
7	Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. <i>Cell Reports</i> , 2019, 29, 162-175.e9.	6.4	26
8	Impact of intramuscular adipose tissue content on short- and long-term outcomes of hepatectomy for colorectal liver metastasis: a retrospective analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 68.	1.9	24
9	Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 138-143.	2.1	23
10	Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 37835-37844.	1.8	23
11	Hepatocellular carcinoma cell sensitivity to $\text{V}\beta 9\text{V}\beta 2$ T lymphocyte-mediated killing is increased by zoledronate. <i>International Journal of Oncology</i> , 2016, 48, 1794-1804.	3.3	13
12	Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection. <i>World Journal of Surgery</i> , 2019, 43, 3153-3160.	1.6	11
13	Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy. <i>World Journal of Surgery</i> , 2020, 44, 2752-2760.	1.6	9
14	Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection. <i>Anticancer Research</i> , 2019, 39, 4431-4440.	1.1	8
15	Feasibility of Laparoscopy-assisted Gastrectomy for Gastric Cancer in Elderly Patients: A Case-Control Study. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2018, 28, 102-107.	0.8	6
16	High postoperative neutrophil-lymphocyte ratio and low preoperative lymphocyte-monocyte ratio predict poor prognosis in gastric cancer patients receiving gastrectomy with positive lavage cytology: a retrospective cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 2295-2303.	1.9	4
17	Systemic Review and Meta-analysis of Impact of Splenectomy for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 3115-3125.	1.3	3
18	Prognostic factors affecting short- and long-term outcomes of gastrectomy for gastric cancer in older patients. <i>Digestive Surgery</i> , 2022, , .	1.2	3

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of dimensional factors in pT1 gastric cancer. <i>Surgical Oncology</i> , 2021, 38, 101584.	1.6	2
20	Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly. <i>European Surgical Research</i> , 2021, 62, 40-52.	1.3	2
21	Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1911-1921.	1.9	2
22	Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. <i>Journal of Immunology and Regenerative Medicine</i> , 2021, 12, 100042.	0.4	0
23	Gastric metastasis from needle tract seeding after endoscopic ultrasound-guided fine needle aspiration of a cancer of the pancreatic body and tail. <i>Suizo</i> , 2020, 35, 394-402.	0.1	0